Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Rosacea Overview | 8 | 1 |
| Therapeutics Development | 9 | 1 |
| Pipeline Products for Rosacea Overview | 9 | 1 |
| Rosacea Therapeutics under Development by Companies | 10 | 1 |
| Rosacea Pipeline Products Glance | 11 | 3 |
| Late Stage Products | 11 | 1 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Rosacea Products under Development by Companies | 14 | 1 |
| Rosacea Companies Involved in Therapeutics Development | 15 | 10 |
| Allergan Plc | 15 | 1 |
| Amorepacific Corporation | 16 | 1 |
| Cell Medica Limited | 17 | 1 |
| Cutanea Life Sciences Inc | 18 | 1 |
| Foamix Pharmaceuticals Ltd. | 19 | 1 |
| Hovione FarmaCiencia SA | 20 | 1 |
| Merz Pharma GmbH &Co. KgaA | 21 | 1 |
| Promius Pharma, LLC | 22 | 1 |
| Sol-Gel Technologies Ltd. | 23 | 1 |
| TWi Pharmaceuticals, Inc. | 24 | 1 |
| Rosacea Therapeutics Assessment | 25 | 9 |
| Assessment by Monotherapy Products | 25 | 1 |
| Assessment by Target | 26 | 2 |
| Assessment by Mechanism of Action | 28 | 2 |
| Assessment by Route of Administration | 30 | 2 |
| Assessment by Molecule Type | 32 | 2 |
| Drug Profiles | 34 | 25 |
| AC-701 Drug Profile | 34 | 1 |
| ACUD-1 Drug Profile | 35 | 1 |
| B-244 Drug Profile | 36 | 1 |
| benzoyl peroxide Drug Profile | 37 | 1 |
| brolucizumab Drug Profile | 38 | 2 |
| CLS-005 Drug Profile | 40 | 1 |
| DFD-29 Drug Profile | 41 | 1 |
| DMT-200 Drug Profile | 42 | 2 |
| DMT-210 Drug Profile | 44 | 1 |
| DMT-220 Drug Profile | 45 | 1 |
| FMX-103 Drug Profile | 46 | 2 |
| incobotulinumtoxin A Drug Profile | 48 | 3 |
| itraconazole Drug Profile | 51 | 1 |
| minocycline Drug Profile | 52 | 1 |
| omiganan pentahydrochloride Drug Profile | 53 | 2 |
| oxymetazoline hydrochloride Drug Profile | 55 | 2 |
| PAC-14028 Drug Profile | 57 | 2 |
| Rosacea Dormant Projects | 59 | 2 |
| Rosacea Discontinued Products | 61 | 1 |
| Rosacea Product Development Milestones | 62 | 9 |
| Featured News &Press Releases | 62 | 1 |
| Sep 28, 2016: Dermata Therapeutics, LLC Announces Positive Top-line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients | 62 | 1 |
| Sep 12, 2016: Foamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea | 62 | 1 |
| Sep 09, 2016: Foamix to Announce Topline Results in Phase 2 Clinical Trial of FMX-103 Minocycline Topical Foam for Moderate-to-Severe Papulopustular Rosacea | 63 | 1 |
| May 24, 2016: Allergan Announces FDA Acceptance of NDA Filing for Oxymetazoline HCI Cream 1.0% | 63 | 1 |
| May 19, 2016: Galderma Laboratories Announces Availability of New Mirvaso (brimonidine) Topical Gel, 0.33% Pump Dispenser for the Treatment of the Persistent Facial Redness of Rosacea | 64 | 1 |
| May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study | 64 | 1 |
| May 03, 2016: Foamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam (FMX103) for Treatment of Papulopustular Rosacea | 65 | 1 |
| Oct 20, 2015: Foamix Announces Enrollment of First Patient in Phase 2 Clinical Trial of FMX103 in Papulopustular Rosacea | 65 | 1 |
| Apr 17, 2014: Treatment for Facial Redness Associated With Rosacea Now Available in the UK | 66 | 1 |
| Feb 26, 2014: mirvaso the first and only treatment targeting the facial redness of rosacea approved by the european commission | 66 | 1 |
| Jan 29, 2014: Galderma Announces the Publication of Positive Results of the Long-Term Study of Mirvaso Gel for Treatment of Persistent Erythema of Rosacea | 67 | 1 |
| Dec 20, 2013: Galderma Receives CHMP Positive Opinion For Mirvaso | 68 | 1 |
| Sep 27, 2013: Galderma Announces Availability of Mirvaso (brimonidine) Topical Gel, 0.33% | 68 | 1 |
| Aug 26, 2013: Galderma Receives FDA Approval of Mirvaso | 69 | 1 |
| Jul 08, 2013: Signum Dermalogix Investigational New Drug Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea | 70 | 1 |
| Appendix | 71 | 2 |
| Methodology | 71 | 1 |
| Coverage | 71 | 1 |
| Secondary Research | 71 | 1 |
| Primary Research | 71 | 1 |
| Expert Panel Validation | 71 | 1 |
| Contact Us | 71 | 1 |
| Disclaimer | 72 | 1 |